查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲伴同性診斷市場：按應用、按最終用戶、按技術、按國家 - 分析和預測（2023-2033）
市場調查報告書
商品編碼
1578771

歐洲伴同性診斷市場：按應用、按最終用戶、按技術、按國家 - 分析和預測（2023-2033）

Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 73 Pages | 商品交期: 1-5個工作天內

價格

2023 年歐洲伴同性診斷市場規模為 11.165 億美元。

預計2023年至2033年該市場將以12.30%的複合年成長率成長，2033年達到35.621億美元。生物醫學影像的進步、伴同性診斷產品認證數量的增加以及癌症發病率的上升正在推動歐洲伴同性診斷市場的擴張。這些因素是支持伴同性診斷和精準醫療在個人化癌症治療中廣泛使用的主要力量。

主要市場統計數據
預測期 2023-2033
2023年評估 11.165 億美元
2033 年預測 35.621 億美元
複合年成長率 12.3%

對精準醫療的需求不斷成長和癌症發病率上升正在推動歐洲伴同性診斷行業的發展。特別是在腫瘤學領域，伴同性診斷對於透過識別最有可能從特定藥物中受益的患者來客製化治療方法至關重要。伴同性診斷是改善治療結果的關鍵工具。因為整個歐洲癌症發生率的上升增加了對此類針對性藥物的需求。

新的伴同性診斷正在得到歐洲監管機構的積極核准，這正在推動市場成長。由於增強型生物醫學影像方法和分子診斷（包括次世代定序（NGS））的開拓，該市場正在擴大。這些進展將使生物標記的識別更加精確，從而實現更精確和客製化的治療。

伴同性診斷不僅在癌症領域變得流行，而且在感染疾病和循環系統疾病等其他治療領域也越來越流行。由於研發支出的增加和有利的法律規範，歐洲的伴同性診斷市場預計將逐步擴大，擴大個體化醫療在整個歐洲大陸的使用並提高患者的治療效果。

該報告研究了歐洲伴同性診斷市場，並提供了市場概述，包括按應用、最終用戶、技術、國家和參與市場的公司概況分類的趨勢。

目錄

執行摘要

第1章 市場

  • 趨勢：當前和未來的影響評估
  • 供應鏈概覽
  • 研究發展回顧
  • 監管狀況
  • 從歷史角度進行伴同性診斷
  • 伴同性診斷 (CDx) 開發的組成部分
  • 伴同性診斷 (CDx)：未來的可能性
  • 市場動態概覽

第2章 區域

  • 區域概況
  • 促進因素和抑制因素
  • 歐洲

第3章市場－競爭基準化分析與公司概況

  • 未來展望
  • 地理評估
    • bioMerieux
    • F. Hoffmann-La Roche Ltd
    • ICON plc
    • QIAGEN NV

第4章調查方法

Product Code: BHP2367SS

Introduction to Europe Companion Diagnostics Market

The Europe companion diagnostics market was valued at $1,116.5 million in 2023 and is expected to reach $3,562.1 million by 2033, growing at a CAGR of 12.30% between 2023 and 2033. Advances in biomedical imaging, a rise in companion diagnostics product approvals, and the rising prevalence of cancer are driving the companion diagnostics market's expansion in Europe. These elements are major forces behind the region's growing use of companion diagnostics and precision medicine in individualized cancer care.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$1,116.5 Million
2033 Forecast$3,562.1 Million
CAGR12.3%

The growing desire for precision medicine and the rising incidence of cancer are driving the companion diagnostics industry in Europe. Particularly in oncology, companion diagnostics are essential for tailoring treatment regimens by identifying patients who are most likely to benefit from particular medicines. Companion diagnostics is a crucial tool for improving treatment outcomes because the increase in cancer incidence throughout Europe has increased the need for such focused medicines.

New companion diagnostics devices are being actively approved by European regulatory bodies, which is driving the market's growth. The market is expanding due to technological developments in molecular diagnostics, including enhanced biomedical imaging methods and next-generation sequencing (NGS). These developments make it possible to identify biomarkers more precisely, which enables more precisely tailored treatments.

Companion diagnostics are becoming popular not only in oncology but also in other treatment domains as infectious and cardiovascular illnesses. The companion diagnostics market in Europe is anticipated to expand gradually due to rising R&D expenditures and a favorable regulatory framework, expanding the use of customized medicine and boosting patient outcomes throughout the continent.

Market Segmentation

Segmentation 1: by Technology

  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Next-Generation Sequencing (NGS)
  • Others

Segmentation 2: by Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Stomach Cancer
  • Melanoma
  • Others

Segmentation 3: by End User

  • Pharmaceutical and Biotechnology Companies
  • Reference Laboratories and Hospitals
  • Others

Segmentation 4: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe companion diagnostics market has been segmented based on various categories, such as technology, application, end user, and country.

Competitive Strategy: The Europe companion diagnostics market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Europe companion diagnostics market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • bioMerieux
  • F. Hoffmann-La Roche Ltd
  • ICON Plc
  • QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Companion Diagnostics Market Trend Analysis
    • 1.1.2 Implementation of Liquid Biopsy-Based Companion Diagnostics
    • 1.1.3 Combining Artificial Intelligence and Companion Diagnostics
  • 1.2 Supply Chain Overview
    • 1.2.1 Value Chain Analysis
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Year)
  • 1.4 Regulatory Landscape
    • 1.4.1 Legal Requirements and Framework by the FDA
    • 1.4.2 Legal Requirements and Framework by the EMA
  • 1.5 CDx from a Historical Perspective
  • 1.6 Constituents for Companion Diagnostics (CDx) Development
  • 1.7 Companion Diagnostics (CDx): Future Potential
  • 1.8 Market Dynamics Overview
    • 1.8.1 Market Drivers
      • 1.8.1.1 Rising Prevalence of Cancer Cases
      • 1.8.1.2 Increasing Product Approvals in the Field of Companion Diagnostics
      • 1.8.1.3 Advancing Biomedical Imaging as the Driving Force for Precision Medicine's Companion Diagnostics
    • 1.8.2 Market Restraints
      • 1.8.2.1 Uncertain Reimbursement Scenario
      • 1.8.2.2 Stringent Regulatory Approval Processes
    • 1.8.3 Market Opportunities
      • 1.8.3.1 Progress in Companion Diagnostics Driven by Continuous Development and Technological Advancements
      • 1.8.3.2 Introduction of Epigenomics-Based Companion Diagnostics

2 Regions

  • 2.1 Regional Summary
  • 2.2 Drivers and Restraints
  • 2.3 Europe
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 Application
    • 2.3.5 Product
    • 2.3.6 France
    • 2.3.7 Application
    • 2.3.8 Product
    • 2.3.9 Germany
    • 2.3.10 Application
    • 2.3.11 Product
    • 2.3.12 U.K.
    • 2.3.13 Application
    • 2.3.14 Product
    • 2.3.15 Spain
    • 2.3.16 Application
    • 2.3.17 Product
    • 2.3.18 Italy
    • 2.3.19 Application
    • 2.3.20 Product
    • 2.3.21 Rest-of-Europe
    • 2.3.22 Application
    • 2.3.23 Product

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Next Frontiers.....
  • 3.2 Geographic Assessment
    • 3.2.1 bioMerieux
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 F. Hoffmann-La Roche Ltd
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 ICON plc
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products/Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 QIAGEN N.V.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products/Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.1 Target Customers
      • 3.2.4.2 Key Personnel
      • 3.2.4.3 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecasta

List of Figures

  • Figure 1: Europe Companion Diagnostics Market, $Million, 2023, 2026, and 2033
  • Figure 2: Europe Companion Diagnostics Market (by Application), $Million, 2022, 2026, and 2033
  • Figure 3: Europe Companion Diagnostics Market (by Technology), $Million, 2022, 2026, and 2033
  • Figure 4: Europe Companion Diagnostics Market (by End User), $Million, 2022, 2026, and 2033
  • Figure 5: Key Industrial Developments in Companion Diagnostics Market, 2023
  • Figure 6: Key Aspects Related to Liquid Biopsy-Based Companion Diagnostics
  • Figure 7: Applications of Digital Diagnostics
  • Figure 8: Supply Chain and Risks within the Supply Chain
  • Figure 9: Europe Companion Diagnostics Market (by Country), January 2021-December 2023
  • Figure 10: Europe Companion Diagnostics (by Year), January 2021-December 2023
  • Figure 11: Evolution of Companion Diagnostics
  • Figure 12: Components Required to Develop Companion Diagnostics
  • Figure 13: Future Prospects of CDx
  • Figure 14: Impact Analysis of Market Navigating Factors, 2023-2033
  • Figure 15: Factors Impacting Reimbursement Scenario
  • Figure 16: Advancements in Companion Diagnostics
  • Figure 17: Future Outlook of Epigenomics
  • Figure 18: Europe Companion Diagnostics Market, $Million, 2022-2033
  • Figure 19: France Companion Diagnostics Market, $Million, 2022-2033
  • Figure 20: Germany Companion Diagnostics Market, $Million, 2022-2033
  • Figure 21: U.K. Companion Diagnostics Market, $Million, 2022-2033
  • Figure 22: Spain Companion Diagnostics Market, $Million, 2022-2033
  • Figure 23: Italy Companion Diagnostics Market, $Million, 2022-2033
  • Figure 24: Rest-of-Europe Companion Diagnostics Market, $Million, 2022-2033
  • Figure 25: Strategic Initiatives, 2021-2023
  • Figure 26: Share of Strategic Initiatives, 2021-2023
  • Figure 27: Data Triangulation
  • Figure 28: Top-Down and Bottom-Up Approach
  • Figure 29: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Companion Diagnostics Market, Opportunities
  • Table 3: Some of FDA Approved Liquid Biopsy CDx Tests
  • Table 4: Cancer Cases Expected between 2020 and 2040
  • Table 5: Product Approvals in the Field of Companion Diagnostics
  • Table 6: Companion Diagnostics Preparation (by Region), $Million, 2022-2033
  • Table 7: Europe Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 8: Europe Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 9: Europe Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 10: France Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 11: France Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 12: France Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 13: Germany Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 14: Germany Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 15: Germany Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 16: U.K. Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 17: U.K. Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 18: U.K. Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 19: Spain Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 20: Spain Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 21: Spain Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 22: Italy Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 23: Italy Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 24: Italy Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 25: Rest-of-Europe Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 26: Rest-of-Europe Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 27: Rest-of-Europe Companion Diagnostics Market (by Technology), $Million, 2022-2033